Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228681 | 0.78 | GPR119 (0.49) | RECQLGPR119MAPTKDM4ETHRB | |
| SCHEMBL25817244 | 0.78 | KDM4E (0.52) | GPR119MAPTKDM4ETHRBPTPN2 | |
| SCHEMBL25817287 | 0.77 | MAPT (0.45) | RECQLGPR119MAPTKDM4ETHRB | |
| SCHEMBL23228682 | 0.77 | SMN1; SMN2 (0.45) | RECQLGPR119MAPTKDM4ETHRB | |
| SCHEMBL25817275 | 0.75 | PDK4 (0.50) | USP2SMN1; SMN2 | |
| SCHEMBL25817270 | 0.74 | HTR2C (0.42) | — | |
| SCHEMBL30493274 | 0.73 | KDM4E (0.52) | GPR119MAPTKDM4ETHRBPTPN2 | |
| SCHEMBL19103521 | 0.73 | KDM4E (0.52) | GPR119MAPTKDM4ETHRBPTPN2 | |
| SCHEMBL29691314 | 0.72 | GPR119 (0.57) | RECQLGPR119MAPTKDM4ETHRB | |
| SCHEMBL23210070 | 0.72 | GPR119 (0.57) | RECQLGPR119MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | RECQL 3812/4885GPR119 43/4885MAPT 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.